Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 4613
Gene Symbol: MYCN
MYCN
0.500 Biomarker disease BEFREE Here we generate humanized models for Sonic Hedgehog (SHH)-subgroup MB via MYCN overexpression in primary human hindbrain-derived neuroepithelial stem (hbNES) cells or iPSC-derived NES cells, which display a range of aggressive phenotypes upon xenografting. iPSC-derived NES tumors develop quickly with leptomeningeal dissemination, whereas hbNES-derived cells exhibit delayed tumor formation with less dissemination. 31786016 2019
Entrez Id: 4613
Gene Symbol: MYCN
MYCN
0.500 Biomarker disease BEFREE Immediate transcriptional changes from this combined MYC blockade were found using RNA-Seq profiling and showed remarkable similarities to changes in MYC target gene expression when MYCN was turned off with doxycycline in our MYCN-inducible animal model for Group 3 MB. 29511348 2018
Entrez Id: 4613
Gene Symbol: MYCN
MYCN
0.500 Biomarker disease BEFREE Literature review identifies the poor prognosis of MYCN-amplified medulloblastomas as well as extraneural metastases; we review the current limitations and future directions of medulloblastoma treatment options. 29343221 2018
Entrez Id: 4613
Gene Symbol: MYCN
MYCN
0.500 GeneticVariation disease BEFREE Rictor/mTORC2 loss delayed timely differentiation of granule cell precursors (GCPs) during cerebellar development, promoting sustained GCP proliferation and medulloblastoma formation, which recapitulated critical features of TP53 mutant sonic hedgehog (SHH) medulloblastomas with GLI2 and/or N-MYC amplification. 29996106 2018
Entrez Id: 4613
Gene Symbol: MYCN
MYCN
0.500 Biomarker disease BEFREE Inhibition of repair processes and comparison of the mouse tumors with human medulloblastomas (n = 68) and glioblastomas (n = 32) identified chromothripsis as associated with MYC/MYCN gains and with DNA repair deficiencies, pointing towards therapeutic opportunities to target DNA repair defects in tumors with complex genomic rearrangements. 30420702 2018
Entrez Id: 4613
Gene Symbol: MYCN
MYCN
0.500 AlteredExpression disease BEFREE Index 2 had diffuse PHOX2B expression, MYCN amplification and no copy number changes of medulloblastoma, in keeping with neuroblastoma. 29758594 2018
Entrez Id: 4613
Gene Symbol: MYCN
MYCN
0.500 Biomarker disease BEFREE Historical risk stratification criteria for medulloblastoma rely primarily on clinicopathological variables pertaining to age, presence of metastases, extent of resection, histological subtypes and in some instances individual genetic aberrations such as MYC and MYCN amplification. 27040285 2016
Entrez Id: 4613
Gene Symbol: MYCN
MYCN
0.500 GeneticVariation disease CLINVAR Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 26619011 2016
Entrez Id: 4613
Gene Symbol: MYCN
MYCN
0.500 AlteredExpression disease BEFREE Amplification of the MYCN is the predominant marker for aggressive NB and correlates with poor prognosis, while c-MYC overexpression is a defining feature of MB subgroups inflected with aggressive biological behavior and increased likelihood of metastasis. 26373717 2016
Entrez Id: 4613
Gene Symbol: MYCN
MYCN
0.500 GeneticVariation disease BEFREE We efficiently induced bioluminescent medulloblastomas expressing eGFP-luciferase in BarTeL mice by infection of a limited number of somatic cGNPs with avian retroviral vectors encoding the active N-terminal fragment of SHH and a stabilized MYCN mutant. 27310018 2016
Entrez Id: 4613
Gene Symbol: MYCN
MYCN
0.500 Biomarker disease BEFREE To better understand the role of MYCN in MB in vitro and in vivo and to aid the development of MYCN-targeted therapeutics we established tumor-derived neurosphere cell lines from the GTML (Glt1-tTA/TRE-MYCN-Luc) genetically engineered mouse model. 25785590 2015
Entrez Id: 4613
Gene Symbol: MYCN
MYCN
0.500 Biomarker disease BEFREE To study this interaction, we investigated a transgenic model of MYCN-driven medulloblastoma and found spontaneous development of Trp53 inactivating mutations. 25533335 2015
Entrez Id: 4613
Gene Symbol: MYCN
MYCN
0.500 Biomarker disease BEFREE Using AGDEX analysis and k-means clustering, we show that the Blbp-cre::Ctnnb1(ex3)(Fl/+)Trp53 (Fl/Fl) mouse model fits well to human WNT medulloblastoma, and that, among various Myc- or Mycn-based mouse medulloblastomas, tumors in Glt1-tTA::TRE-MYCN/Luc mice proved to be most specific for human group 3 medulloblastoma. 24871706 2014
Entrez Id: 4613
Gene Symbol: MYCN
MYCN
0.500 Biomarker disease BEFREE MYC and MYCN amplification can be reliably assessed by aCGH in medulloblastoma. 23578955 2013
Entrez Id: 4613
Gene Symbol: MYCN
MYCN
0.500 GeneticVariation disease BEFREE We aimed to evaluate the prognostic value of this alteration alone and in combination with biological modifiers in 67 pediatric medulloblastomas with MYCN amplification (MYCN-MB). 22160402 2012
Entrez Id: 4613
Gene Symbol: MYCN
MYCN
0.500 Biomarker disease BEFREE This mouse model should significantly accelerate understanding and treatment of the most aggressive form of medulloblastoma and infers distinct roles for MYC and MYCN in tumorigenesis. 22340591 2012
Entrez Id: 4613
Gene Symbol: MYCN
MYCN
0.500 AlteredExpression disease BEFREE This finding also confirms the importance of impairment of the MYC/MAX/MXD1 axis in the development of aggressive neural tumors, because MYCN overexpression is an established genetic hallmark of malign neuroblastoma, and it is likely that MXI1 plays a relevant role in the development of medulloblastoma and glioblastoma. 22706201 2012
Entrez Id: 4613
Gene Symbol: MYCN
MYCN
0.500 AlteredExpression disease BEFREE MYCN is a transcription factor that is expressed during the development of the neural crest and its dysregulation plays a major role in the pathogenesis of pediatric cancers such as neuroblastoma, medulloblastoma and rhabdomyosarcoma. 21731748 2011
Entrez Id: 4613
Gene Symbol: MYCN
MYCN
0.500 Biomarker disease BEFREE Cytogenetic analysis of a large, non-overlapping cohort of Shh-medulloblastomas (n = 151) revealed significant over-representation of chromosome 10q deletion (P < 0.001) and MYCN amplification (P < 0.05) in pediatric Shh cases compared with adults. 21681522 2011
Entrez Id: 4613
Gene Symbol: MYCN
MYCN
0.500 AlteredExpression disease BEFREE We found that Sna1 directly induced transcription of N-Myc in human medulloblastoma cells and that depletion of N-Myc ablated the Sna1-induced proliferation and transformation. 21646478 2011
Entrez Id: 4613
Gene Symbol: MYCN
MYCN
0.500 Biomarker disease BEFREE MYCN-driven MB showed either classic or LCA pathologies, with Shh signaling activated in approximately 5% of tumors, demonstrating that MYCN can drive MB independently of Shh. 20478998 2010
Entrez Id: 4613
Gene Symbol: MYCN
MYCN
0.500 GeneticVariation disease BEFREE TP53 mutation status was not associated with unfavorable prognosis (P = .63) and was not linked to 17p allelic loss but was over-represented in the prognostically favorable WNT subgroup of MB as defined by CTNNB1 mutation (seven of 35 TP53-mutated tumors v 14 of 271 TP53 wild-type tumors; P = .005) and in tumors carrying high-level MYCN amplification (seven of 21 TP53-mutated tumors v 14 of 282 TP53 wild-type tumors; P = .001). 21060032 2010
Entrez Id: 4613
Gene Symbol: MYCN
MYCN
0.500 Biomarker disease BEFREE Whereas MYC/MYCN oncogene amplifications had a high prognostic value in pediatric MB, these aberrations were rarely observed in adult tumors. 20479417 2010
Entrez Id: 4613
Gene Symbol: MYCN
MYCN
0.500 Biomarker disease CTD_human Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. 19270706 2009
Entrez Id: 4613
Gene Symbol: MYCN
MYCN
0.500 AlteredExpression disease BEFREE Medulloblastomas in which miR-17/92 was up-regulated also had elevated levels of MYC/MYCN expression. 19351822 2009